NF k-B is also inhibited by aspirin. IT also inhibits Chlamydia pneumoniae, so we have a citation in our CPn archives on this. Here is a link to that research
http://www.CPn Help.org/pdfs/Aspirin:Cpn.pdf
read this paper and you will see that ASA inhibits NF-kB through a mechanism unrelated to CPn (I had a hard time with the link as it keeps putting a space in it after cpn but all the words are there for the interested person)
Aspirin works fairly well in people with RA to reduce inflammation but once again we have old bugaboo issue of people's disease progressing in spite of this reduced inflammatory activity.
Aspirin has also been tested in MS and found to be useless. Here is a blerb on a NMSS site that mentions this:
Quote: Aspirin and sodium salicylate are two moderately anti-inflammatory agents that affect the prostaglandin pathways. Peptic ulceration and gastrointestinal bleeding are two side effects common to these agents
which appear to have no effect on MS. Aspirin may be beneficial for pain relief, but acetaminophen has fewer side effects and certain advantages over aspirin. Neither are used to treat MS".end quote
Since ASA inhibits NF-kB and it has also been tested in MS and found to be ineffective, I submit that this is another blind ally for research.
I am in the "MS is not autoimmune " camp and therefore the constant focus on the proinflammatory cytokines and the vast amounts of research dollars spent looking for ways to inhibit inflammation are to me very off topic. NF-kB is just another of these approaches. ( For those in the CPn camp of course the issue that CPn causes upregulation of NF-kB is yet another smoking gun for CPn being potentially related to MS.)
In the first post a hint of the size of the problem is there when the authors state the difficulty they had in creating a mouse that did not express NF-kB....they DIED in the womb. This suggests how many problems will ben encountered should they find a way to ihnibit our NF-kB. I would not invest in a company making this product ! I'll be much happier to see more in the neuroprotective and regeneration research arenas.
Marie